



Anti-Fibrotic Drug Development

November 13-14 2017, Boston, USA

Translating Fibrotic Mechanisms into Clinically Effective Therapeutics

A unique opportunity for drug developers focused on NASH, IPF, Scleroderma, Cancer and other fibrotic diseases to participate in cross-disciplinary discussions

Expert speakers include:



Ray Jupp
Vice President
Immunology Research
UCB



Richard Marshall
Vice President, Head
Fibrosis
GSK



Lisa Hazelwood
Principal Scientist, Liver
Disease & Fibrosis
AbbVie



Peter Blume-Jensen
Chief Scientific Officer
Xtuit Pharmaceuticals



Alexey Lugovskoy
Chief Development
Officer
Morphic Therapeutics



Seth Porter
Vice President
FibroGen

■ ■ This was a highly informative conference in an exploding field. It brought together in one place all of the major people working in this field ■ ■

Forward Ventures

Welcome to Anti-Fibrotic Drug Development 2017

Translating Fibrotic Mechanisms into Clinically Effective Therapeutics

Anti-Fibrotic Drug Development (AFDD) will solve the challenges drug developers face when translating fibrotic mechanisms into clinically effective therapeutics.

This unique summit will be an opportunity for drug developers focused on organ-specific indications to participate in a cross-disciplinary, multi-organ discussion in order to gain new insights into their anti-fibrotic drug development research.

Attending this comprehensive forum will enable you to:

- Deepen your understanding on **cross-organ fibrotic mechanisms** which are driving pathology changes in humans
- Develop **more reliable in vivo models** which recapitulate human fibrosis and effectively translate into clinical development
- Identify **reliable biomarkers to improve clinical trial design** and quickly determine the efficacy of your compound

Join the field's thought-leaders at AFDD to learn and engage with leading experts and accelerate your anti-fibrotic drug candidate development.

Past Attendee Feedback:

■■ An effective forum to network and learn the most recent progress on several areas ■■

MedImmune

■■ Very valuable useful information – one of the best meetings I've ever attended. Should be an annual meeting ■■

Takeda


■■ Strong program, great speakers and a genuine focus on identifying solutions ■■

Novartis

Top 5 Reasons to attend AFDD 2017

1.

Exploring commonalities in fibrosis mechanisms & pathways to drive a more powerful therapeutic response




2.

Deepening understanding of different mechanisms driving fibrosis progression to develop the next generation of more efficacious anti-fibrotic compounds



3.

Developing preclinical models which are more predictive and relevant of human fibrosis and confidently translate into the clinic



4.

Investigating recent findings in utilizing surrogate biomarkers as clinical endpoints to quickly determine the efficacy of anti-fibrotic drugs



5.

Improve patient response from lessons learned in recruiting homogenous and responsive patient populations



Your Expert Speakers



Lisa Hazelwood
Principal Scientist,
Liver Disease &
Fibrosis
AbbVie



Michael Foley
Chief Scientific Officer
AdAlta



Shuyu Ren
Scientist II
Biogen



Ignacio Juncadella
Principal Scientist,
Immunology &
Respiratory Disease
Boehringer Ingelheim



Seth Porter
Vice President
FibroGen



Ning Ding
Scientist
Genentech



Jun Sonoda
Senior Scientist,
Cancer Immunology
Genentech



Richard Marshall
Vice President, Head
Fibrosis
GSK



Terence Ryan
Chief Scientific Officer
iBio



Corrie Gallant-Behm
Research Scientist
**miRagen
Therapeutics**



Alexey Lugovskoy
Chief Development
Officer
**Morphic
Therapeutics**



Nick Pullen
Senior Director, Head
Emerging Sciences
Pfizer



Zhiyong Yang
Associate Research
Fellow & Research
Project Leader,
Inflammation &
Immunology
Pfizer



Rick Jack
President & Chief
Scientific Officer
Promedior



Stefan Wawersik
Associate Director,
Discovery Biology
Scholar Rock



Casey Logan
Chief Business Officer
Tracon Pharma



Ray Jupp
Vice President,
Immunology
Research
UCB



Peter Blume-Jensen
Chief Scientific Officer
**Xtuit
Pharmaceuticals**

Conference Day One | Monday November 13 2017

 Richard Marshall , Vice President, Head Fibrosis, GSK	8.20 Chair's Opening Remarks
 Alexey Lugovskoy , Morphic Therapeutics  Nick Pullen , Pfizer  Lisa Hazelwood , AbbVie	8.30 Key Opinion Leader Panel Discussion: Comprehensive Review of Anti-Fibrotic Drug Development - Enhance understanding of fibrotic processes and mechanisms that branch between organs - Review the latest progress in developing more reliable and relevant preclinical fibrosis models and effectively translate into clinical development - Explore advances in identifying and validating biomarkers which demonstrate the diagnosis, progression and regression of fibrosis
 Peter Blume-Jensen , Chief Scientific Officer, Xtuit Pharmaceuticals	9.00 Investigating Key Mechanisms of Fibrosis Progression Across Different Organs Exemplified by Liver Disease - Explore fibrotic processes across diseases and identify microenvironment mechanisms that are driving fibrosis progression - Development of microenvironment-targeted drugs against fibrosis and desmoplasia - Identify clinically relevant biomarkers for an early clinical Proof-of-Concept for efficacy
	9.30 Speed Networking This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in anti-fibrotic drug development and establish meaningful business relationships.

10.30 Morning Refreshments

Exploring Cross-Organ Anti-Fibrotic Mechanisms

 Lisa Hazelwood , Principal Scientist, Liver Disease & Fibrosis, AbbVie	11.00 Looking Beyond Organ Fibroblast Processes: Exploring Commonalities in Fibrosis Pathways - Review mechanisms that branch between organs - Enhance understanding of fibrotic processes by exploring common cell types in fibrotic indications - Develop new models of human fibrotic disease to study targets and mechanisms, and explore novel biomarkers of fibrosis
 Ignacio Juncadella , Principal Scientist, Immunology & Respiratory Disease, Boehringer Ingelheim	11.30 The Immunology of Fibrosis: Exploring Immune & Inflammatory Mechanisms that are Driving Fibrosis - The inter-relationship between immune cells and the fibrotic response - Immune related pathways, disease pathogenesis and remodeling associated processes - Integration of tissue 'signals', inflammatory pathways and fibrosis

12.00 Lunch & Networking


Discovery & Development of Novel Anti-Fibrotics

 Shuyu Ren , Scientist II, Biogen	1.00 Developing Next Generation Anti-Fibrotic Therapeutics Utilizing Wnt Co-Receptor LRP6 - Improve understanding of cross-talk of different signalling pathways and explore key regulation mechanisms - Learn how CTGF could cross-activate Wnt co-receptor LRP6 which activates the downstream smad2/3 signaling pathway, which is a key downstream mediator of TGFβ signaling in fibrosis - Discover how inhibition of critical central mediators could provide a more efficient therapeutic target for next generation of anti-fibrotic compounds
--	--

 Michael Foley, Chief Scientific Officer, AdAlta	1.30 i-Bodies: A Novel Therapeutic Approach For IPF - Highlighting the critical role the chemokine receptor, CXCR4, has shown in the development of Idiopathic Pulmonary Fibrosis - Revealing AdAlta's unique human single domain protein platform to identify a novel i-body, AD-114, that specifically antagonizes CXCR4 and shows both anti-inflammatory and anti-fibrotic effects in a bleomycin induced model of IPF. - Demonstrating the anti-fibrotic properties of AD-114 in multiple animal and in vitro models of fibrosis, suggesting that it may have broad applications in fibrosis of organs other than the lung
 Zhiyong Yang, Associate Research Fellow & Research Project Leader, Inflammation & Immunology, Pfizer	2.00 Assessing the Feasibility of Neutralizing a Well-Validated Anti-inflammation/Anti-Fibrotic Target Using a Therapeutic Antibody More details to follow

2.30 Afternoon Refreshments & Networking

Developing Reliable & Representative Preclinical Models to Confidently & Quickly Progress to Clinical Development

 Rick Jack, President & Chief Scientific Officer, Promedior	3.30 What are the Limitations and Full Potential of Modelling Fibrosis Preclinically? - How representative can preclinical models be of actual disease? - What are the commonalities of fibrotic pathologies? - Preclinical evaluation of PRM-151 in preclinical models of liver, kidney and retinal disease
 Terence Ryan, Chief Scientific Officer, iBio	4.00 A Plant-Manufactured Biologic Reverses Established Pulmonary Fibrosis in Mouse Models of Disease & Human Fibrotic Tissue Explants - A fusion protein containing a peptide from endostatin displays unusual biophysical and pharmacologic properties - When administered by injection or orally, it reverses established pulmonary fibrosis in mouse models of disease - This biotherapeutic protein reduces the collagen content of human lung tissue from fibrosis patients when added to ex vivo cultures
 Stefan Wawersik, Associate Director, Discovery Biology, Scholar Rock	4.30 Improve Translatability of In Vivo Models for Fibrotic Disease - Discovery efforts focusing on the TGF beta superfamily as mediators of fibrogenesis - Applying insight into proTGF beta complexes to therapeutically target the connective tissue microenvironment - Which models; when and how representative are the results?
 Richard Marshall, Vice President, Head Fibrosis, GSK	5.00 Chair's Closing Remarks
	5.15 Scientific Poster Session This session is a great opportunity to introduce yourself to the attendees that you would like to have more in depth conversations with. This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in anti-fibrotic drug development and establish meaningful business relationships.

Conference Day Two | Tuesday November 14 2017

 Richard Marshall , Vice President, Head Fibrosis, GSK	8.50 Chair's Opening Remarks
 Casey Logan , Chief Business Officer, Tracon Pharma	9.00 TRC205: Explore the Application of an Oncology Therapeutic for Fibrosis • TRC205, a second generation antibody to endoglin, is undergoing preclinical testing for fibrosis • Review marked reduction in cutaneous neurofibromatosis in a sarcoma patient following dosing with TRACON's TRC105 and Votrient® (pazopanib) in a Phase 2 clinical trial, suggesting the potential of an endoglin antibody as an effective treatment for patients with fibrosis • Explore subsequent preclinical development of TRC205 in liver and cardio fibrosis in vivo models
 Seth Porter , Vice President, FibroGen	9.30 Mechanistic Relationships Between Fibrosis and Cancer: Translational Lessons Learned • Importance of addressing multiple pathways associated with fibrosis • Using pre-clinical and clinical studies to improve understanding of fibrotic disease • Translation of pre-clinical and clinical endpoints in development of anti-fibrotic therapy
 Ning Ding , Scientist, Immunology, Genentech	10.00 Understanding Core Mechanisms of Tissue Fibrosis: Lessons Learned from Targeting Key Pro-Fibrotic Pathways • Define core mechanisms underlying fibrotic response across organs • Review examples of core pathways that drive fibrosis across organs • Explore the feasibility of targeting core pathways as anti-fibrotic therapy and beyond

10.30 Morning Refreshments & Networking

Strategies for Biomarker Discovery in Fibrotic Disease

 Ray Jupp , Vice President, Immunology Research, UCB	11.00 Moving Towards Personalized Medicine: Overview of Development of Predictive Biomarkers of Fibrosis • Review advances in identifying and validating biomarkers • Explore recent findings in utilizing surrogate biomarkers as clinical endpoints to quickly determine the efficacy of anti-fibrotic candidate • From the clinic to the bench: leverage clinical biomarker data of validated pathways to improve preclinical drug development & robustly translate into the clinic
	11.30 Think Tank Roundtable Sessions More practical and highly interactive breakout roundtables where attendees can crowd-source solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. No more sitting quietly, this is a dedicated opportunity for you to voice your experiences and identify unique solutions.
	12.30 Moderator Feedback & Audience Debate Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtables, they will present back to the entire delegation as part of a panel discussion for information dissemination.

1.00 Lunch & Networking

Accelerate the Future Development of Anti-Fibrotic Compounds

 Corrie Gallant-Behm , Research Scientist, miRagen Therapeutics	2.00 Innovative RNA Based Therapeutics as a Modality for the Effective Treatment of Multiple Fibrotic Conditions • microRNAs are powerful regulators of extracellular matrix production, pro-fibrotic signaling, and the cellular changes that accompany fibrosis • Demonstrating proof of concept in cutaneous fibrosis before looking at pipeline expansion • Effectiveness of miR-29 and miR-155 as case study examples
 Jun Sonoda , Senior Scientist, Cancer Immunology, Genentech	2.30 Explore the Discovery & Development of Next Generation Anti-Fibrotic Compounds • Learn from the ongoing clinical development of a bispecific anti-FGFR1/KLB mAb which targets metabolic modulation in NASH • Explore the pre-clinical stage program targeting activated fibroblasts
A selection of speakers from the day's faculty	3.00 Panel Discussion: What Does the Future Hold for Anti-Fibrotic Drug Development? Cross Industry Perspectives • Lessons learned from progress in the field so far • What still needs to be done? • How do different stakeholders need to contribute?
 Richard Marshall , Vice President, Head Fibrosis, GSK	3.45 Chair's Closing Remarks

Great meeting. I have been working in this field for over 10 years, this meeting brings the best scientists with state of the art experience. Great job
Bristol Myers Squibb

Highly interactive meeting with a right balance between opportunities to meet the other participants and the many interesting presentations
Ablynx



WHY PARTNER?



From research with **BMS, GSK, Morphic Therapeutics** and many others we've been told drug developers are **actively seeking more specific, cost and time effective solutions** to enable them to translate fibrotic mechanisms into clinically effective therapeutics.

Partnering with this summit is your opportunity to **elevate your company's standing in the fibrosis field**. Your brand, your message, your reputation showcased in front of the leading minds of anti-fibrotic drug development.


Whether you're on the brink of **validating your approach and need to communicate this exciting progress** or you're simply looking to **generate leads, put names to faces or get a grasp of this fast-paced market**, you can rely on our ability to advise on, and deliver, the right solution for you.

To learn more about how we can support your efforts get in touch today at sponsor@hansonwade.com

SENIORITY OF ATTENDEES*



TYPES OF COMPANIES ATTENDING*



Large & Small Pharma

Biotech

CROs

Preclinical Modelling Companies

Non-Invasive Diagnostic Companies

Academics

*Expected attendees for 2017 based on Hanson Wade Life Science event attendee analysis

WHO WILL ATTEND AFDD?



*Based on previous attendance at NASH Summit & IPF Summit 2017

BECOME A PARTNER



Jakub Nunuk
Partnership Manager
Tel: +1 212 537 5898
Email: sponsor@hansonwade.com

READY TO REGISTER?

3 EASY WAYS TO BOOK

-  www.afdd-summit.com/register
-  Tel: +1 212 537 5898
-  Email: register@hansonwade.com

- 1** Deepen your understanding on cross-organ fibrotic mechanisms which are driving pathology changes in humans.
- 2** Develop more reliable in vivo models which recapitulate human fibrosis and effectively translate into clinical development.
- 3** Identify reliable secondary biomarkers to improve clinical trial design and quickly determine the efficacy of your compound.

Team Discounts*

- 10% discount – 3 delegates
- 15% discount – 4 delegates
- 20% discount – 5 or more delegates

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

SECURE YOUR PLACE

	Register & pay by August 18 2017	Register & pay by September 8 2017	Register & pay by October 6 2017	Standard Pricing
Industry Pricing	\$2399 (save \$300)	\$2499 (save \$200)	\$2599 (save \$100)	\$2699
Academic Pricing	\$1299 (save \$300)	\$1399 (save \$200)	\$1499 (save \$100)	\$1599

Excellent networking opportunity. Excellent exchange on science, clinical trials and economic challenges **Arronax**



VENUE

Hyatt Regency Boston
1 Ave de Lafayette, Boston, MA 02111, USA

For further information or assistance, please
www.boston.regency.hyatt.com/en/hotel/home

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Hanson Wade reserves the right to postpone or cancel an event, to change the location or alter the advertised speakers. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH

Code: 8155